Press Releases

Press Releases

November 2, 2022
CytomX Therapeutics to Present at Upcoming November Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Nov. 02, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy , D.Phil ., chief executive officer and chairman, will participate in the following
Additional Formats
September 7, 2022
CytomX Therapeutics Presents Overview of Conditionally-Activated Antibody-Drug Conjugate (ADC) Programs Including Next Generation EpCAM-Targeting CX-2051
- Presentation at World ADC Conference in San Diego - - CX-2051 integrates CytomX core platform expertise to potentially maximize therapeutic window - SOUTH SAN FRANCISCO, Calif. , Sept. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally
Additional Formats
Displaying 1 - 10 of 28